Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

A novel role of MMP2 in regulating platelet NOX2 activation.

Nocella C, Cammisotto V, Bartimoccia S, Castellani V, Loffredo L, Pastori D, Pignatelli P, Sanguigni V, Violi F, Carnevale R.

Free Radic Biol Med. 2020 Apr 5. pii: S0891-5849(20)30359-2. doi: 10.1016/j.freeradbiomed.2020.03.033. [Epub ahead of print]

PMID:
32268176
2.

PCSK9 Regulates Nox2-Mediated Platelet Activation via CD36 Receptor in Patients with Atrial Fibrillation.

Cammisotto V, Pastori D, Nocella C, Bartimoccia S, Castellani V, Marchese C, Scavalli AS, Ettorre E, Viceconte N, Violi F, Pignatelli P, Carnevale R.

Antioxidants (Basel). 2020 Apr 2;9(4). pii: E296. doi: 10.3390/antiox9040296.

3.

Correction to: Reduced Lysosomal Acid Lipase Activity in Blood and Platelets Is Associated With Nonalcoholic Fatty Liver Disease.

Ferri F, Mischitelli M, Tozzi G, Messina E, Mignini I, Mazzuca S, Pellone M, Parisse S, Marrapodi R, Visentini M, Baratta F, Del Ben M, Pastori D, Perciballi R, Attilia ML, Carbone M, De Santis A, Violi F, Angelico F, Corradini SG.

Clin Transl Gastroenterol. 2020 Apr;11(4):e00171. doi: 10.14309/ctg.0000000000000171. No abstract available.

PMID:
32251015
4.

Integrated care management of patients with atrial fibrillation-far from optimal.

Pignatelli P, Violi F, Pastori D.

Pol Arch Intern Med. 2020 Mar 27;130(3):176-178. doi: 10.20452/pamw.15260. Epub 2020 Mar 27. No abstract available.

5.

Determinants of low-quality warfarin anticoagulation in patients with mechanical prosthetic heart valves. The nationwide PLECTRUM study.

Pastori D, Lip GYH, Poli D, Antonucci E, Rubino L, Menichelli D, Saliola M, Violi F, Palareti G, Pignatelli P; Italian Federation of Anticoagulation Clinics (FCSA).

Br J Haematol. 2020 Feb 20. doi: 10.1111/bjh.16528. [Epub ahead of print]

PMID:
32080833
6.

Von Willebrand and Factor VIII Portosystemic Circulation Gradient in Cirrhosis: Implications for Portal Vein Thrombosis.

Praktiknjo M, Trebicka J, Carnevale R, Pastori D, Queck A, Ettorre E, Violi F.

Clin Transl Gastroenterol. 2020 Feb;11(2):e00123. doi: 10.14309/ctg.0000000000000123.

PMID:
32032127
7.

Upper extremity deep vein thrombosis treated with direct oral anticoagulants: a multi-center real world experience.

Porfidia A, Agostini F, Giarretta I, Tonello D, Pastori D, Pignatelli P, Santoliquido A, Sartori M, Lessiani G, Visonà A, Donadini MP, Pola R.

J Thromb Thrombolysis. 2020 Feb 1. doi: 10.1007/s11239-020-02044-4. [Epub ahead of print]

PMID:
32008208
8.

Seronegative antiphospholipid syndrome: refining the value of "non-criteria" antibodies for diagnosis and clinical management.

Pignatelli P, Ettorre E, Menichelli D, Pani A, Violi F, Pastori D.

Haematologica. 2020 Mar;105(3):562-572. doi: 10.3324/haematol.2019.221945. Epub 2020 Jan 30. Review.

9.

Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study.

Baratta F, Pastori D, Angelico F, Balla A, Paganini AM, Cocomello N, Ferro D, Violi F, Sanyal AJ, Del Ben M.

Clin Gastroenterol Hepatol. 2019 Dec 27. pii: S1542-3565(19)31506-X. doi: 10.1016/j.cgh.2019.12.026. [Epub ahead of print]

PMID:
31887443
10.

Increased liver localization of lipopolysaccharides in human and experimental non-alcoholic fatty liver disease.

Carpino G, Del Ben M, Pastori D, Carnevale R, Baratta F, Overi D, Francis H, Cardinale V, Onori P, Safarikia S, Cammisotto V, Alvaro D, Svegliati-Baroni G, Angelico F, Gaudio E, Violi F.

Hepatology. 2019 Dec 6. doi: 10.1002/hep.31056. [Epub ahead of print]

PMID:
31808577
11.

Prevalence and Impact of Nonalcoholic Fatty Liver Disease in Atrial Fibrillation.

Pastori D, Sciacqua A, Marcucci R, Farcomeni A, Perticone F, Del Ben M, Angelico F, Baratta F, Pignatelli P, Violi F; ATHERO-AF study group.

Mayo Clin Proc. 2020 Mar;95(3):513-520. doi: 10.1016/j.mayocp.2019.08.027. Epub 2019 Nov 18.

PMID:
31753536
12.

Multiple Arterial Thrombosis in Seronegative Antiphospholipid Syndrome: Need for New Diagnostic Criteria?

Pastori D, Misasi R, Sorice M, Cribari F, Menichelli D, Violi F, Pignatelli P.

Eur J Case Rep Intern Med. 2019 Sep 23;6(10):001180. doi: 10.12890/2019_001180. eCollection 2019.

13.

Anticoagulants in Atrial Fibrillation and Liver Disease.

Pignatelli P, Pastori D, Violi F.

J Am Coll Cardiol. 2019 Nov 12;74(19):2436. doi: 10.1016/j.jacc.2019.07.090. No abstract available.

PMID:
31699289
14.

Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry.

Pastori D, Antonucci E, Violi F, Palareti G, Pignatelli P; START2 Registry Investigators ‡; START2 Registry Investigators <xref ref-type="author-note" rid="jah34460-note-1002"><sup>‡</sup></xref>.

J Am Heart Assoc. 2019 Nov 5;8(21):e012596. doi: 10.1161/JAHA.119.012596. Epub 2019 Oct 28.

15.

Serum albumin and risk of cardiovascular events in primary and secondary prevention: a systematic review of observational studies and Bayesian meta-regression analysis.

Pignatelli P, Farcomeni A, Menichelli D, Pastori D, Violi F.

Intern Emerg Med. 2020 Jan;15(1):135-143. doi: 10.1007/s11739-019-02204-2. Epub 2019 Oct 11. Review.

PMID:
31605272
16.

Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry).

Calabrò P, Moscarella E, Gragnano F, Cesaro A, Pafundi PC, Patti G, Cavallari I, Antonucci E, Cirillo P, Pignatelli P, Palareti G, Sasso FC, Pengo V, Gresele P, Marcucci R; START-ANTIPLATELET collaborators, Conte M, Fimiani F, Di Serafino L, Del Pinto M, Denas G, Pastori D, Eleonora C, Fierro T.

Am J Cardiol. 2019 Dec 1;124(11):1662-1668. doi: 10.1016/j.amjcard.2019.08.030. Epub 2019 Sep 6.

PMID:
31585697
17.

Very elderly patients with venous thromboembolism on oral anticoagulation with VKAs or DOACs: Results from the prospective multicenter START2-Register Study.

Poli D, Antonucci E, Bertù L, Vignini E, Ruocco L, Mastroiacovo D, Paparo C, Pastori D, Testa S, Ageno W, Palareti G; coordinator of START2 Register.

Thromb Res. 2019 Nov;183:28-32. doi: 10.1016/j.thromres.2019.08.024. Epub 2019 Aug 26.

18.

Reduced lysosomal acid lipase activity: A new marker of liver disease severity across the clinical continuum of non-alcoholic fatty liver disease?

Baratta F, Pastori D, Ferro D, Carluccio G, Tozzi G, Angelico F, Violi F, Del Ben M.

World J Gastroenterol. 2019 Aug 14;25(30):4172-4180. doi: 10.3748/wjg.v25.i30.4172. Review.

19.

Lysosomal acid lipase activity and liver fibrosis in the clinical continuum of non-alcoholic fatty liver disease.

Baratta F, Pastori D, Tozzi G, D'Erasmo L, Di Costanzo A, Arca M, Ettorre E, Ginanni Corradini S, Violi F, Angelico F, Del Ben M.

Liver Int. 2019 Dec;39(12):2301-2308. doi: 10.1111/liv.14206. Epub 2019 Aug 21.

PMID:
31392821
20.

Interaction between serum endotoxemia and proprotein convertase subtilisin/kexin 9 (PCSK9) in patients with atrial fibrillation: A post-hoc analysis from the ATHERO-AF cohort.

Pastori D, Ettorre E, Carnevale R, Nocella C, Bartimoccia S, Del Sordo E, Cammisotto V, Violi F, Pignatelli P; Atherosclerosis in Atrial Fibrillation (ATHERO-AF) Study Group.

Atherosclerosis. 2019 Oct;289:195-200. doi: 10.1016/j.atherosclerosis.2019.07.002. Epub 2019 Jul 4.

PMID:
31303312
21.

Off-label use of ceftaroline fosamil: A systematic review.

Pani A, Colombo F, Agnelli F, Frantellizzi V, Baratta F, Pastori D, Scaglione F.

Int J Antimicrob Agents. 2019 Nov;54(5):562-571. doi: 10.1016/j.ijantimicag.2019.06.025. Epub 2019 Jul 3. Review.

PMID:
31279152
22.

Left Atrium Dilatation and Left Ventricular Hypertrophy Predispose to Atrial Fibrillation in Patients With Community-Acquired Pneumonia.

Cangemi R, Calvieri C, Taliani G, Pignatelli P, Morelli S, Falcone M, Pastori D, Violi F; SIXTUS study group.

Am J Cardiol. 2019 Sep 1;124(5):723-728. doi: 10.1016/j.amjcard.2019.05.051. Epub 2019 Jun 6.

PMID:
31266594
23.

Does the Coexistence of Chronic Obstructive Pulmonary Disease and Atrial Fibrillation Affect Nox2 Activity and Urinary Isoprostanes Excretion?

Pastori D, Andreozzi P, Carnevale R, Bartimoccia S, Limaj S, Melandri S, Brunori M, Spallacci G, Violi F, Pignatelli P.

Antioxid Redox Signal. 2019 Oct 10;31(11):786-790. doi: 10.1089/ars.2019.7811. Epub 2019 Jul 23.

PMID:
31250672
24.

Real-world efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.

Violi F, Pastori D.

Intern Emerg Med. 2019 Nov;14(8):1199-1201. doi: 10.1007/s11739-019-02135-y. Epub 2019 Jun 27. No abstract available.

PMID:
31250259
25.

Atrial high-rate episodes and risk of major adverse cardiovascular events in patients with cardiac implantable electronic devices.

Pastori D, Miyazawa K, Li Y, Székely O, Shahid F, Farcomeni A, Lip GYH.

Clin Res Cardiol. 2020 Jan;109(1):96-102. doi: 10.1007/s00392-019-01493-z. Epub 2019 May 29.

PMID:
31144064
26.

Relationship of Antiphospholipid Antibodies to Risk of Dementia: A Systematic Review.

Bucci T, Menichelli D, Pignatelli P, Triggiani M, Violi F, Pastori D.

J Alzheimers Dis. 2019;69(2):561-576. doi: 10.3233/JAD-181294.

PMID:
31104025
27.

Statins and non-alcoholic fatty liver disease.

Angelico F, Baratta F, Pastori D, Del Ben M.

Liver Int. 2019 Sep;39(9):1787. doi: 10.1111/liv.14134. Epub 2019 Jun 10. No abstract available.

PMID:
31081583
28.

Atrial high-rate episodes and thromboembolism in patients without atrial fibrillation: The West Birmingham Atrial Fibrillation Project.

Li YG, Miyazawa K, Pastori D, Szekely O, Shahid F, Lip GYH.

Int J Cardiol. 2019 Oct 1;292:126-130. doi: 10.1016/j.ijcard.2019.04.055. Epub 2019 Apr 17.

PMID:
31031080
29.

Tailored Practical Management of Patients With Atrial Fibrillation: A Risk Factor-Based Approach.

Pastori D, Menichelli D, Gingis R, Pignatelli P, Violi F.

Front Cardiovasc Med. 2019 Mar 12;6:17. doi: 10.3389/fcvm.2019.00017. eCollection 2019. Review.

30.

Update and Unmet Needs on the Use of Nonvitamin K Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation.

Menichelli D, Ettorre E, Pani A, Violi F, Pignatelli P, Pastori D.

Curr Probl Cardiol. 2019 Feb 27:100410. doi: 10.1016/j.cpcardiol.2019.02.002. [Epub ahead of print] Review.

PMID:
30904157
31.

Immunoglobulin G (IgG) anticardiolipin antibodies and recurrent cardiovascular events. A systematic review and Bayesian meta-regression analysis.

Pastori D, Bucci T, Triggiani M, Ames PRJ, Parrotto S, Violi F, Pignatelli P, Farcomeni A.

Autoimmun Rev. 2019 May;18(5):519-525. doi: 10.1016/j.autrev.2019.03.005. Epub 2019 Mar 4.

PMID:
30844560
32.

Nox2-mediated platelet activation by glycoprotein (GP) VI: Effect of rivaroxaban alone and in combination with aspirin.

Cammisotto V, Carnevale R, Nocella C, Stefanini L, Bartimoccia S, Coluccia A, Silvestri R, Pignatelli P, Pastori D, Violi F.

Biochem Pharmacol. 2019 May;163:111-118. doi: 10.1016/j.bcp.2019.02.016. Epub 2019 Feb 13.

PMID:
30771281
33.

Atrial high rate episodes in patients with cardiac implantable electronic devices: implications for clinical outcomes.

Miyazawa K, Pastori D, Li YG, Székely O, Shahid F, Boriani G, Lip GYH.

Clin Res Cardiol. 2019 Sep;108(9):1034-1041. doi: 10.1007/s00392-019-01432-y. Epub 2019 Feb 13.

34.

Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy.

Pastori D, Eikelboom JW, Anand SS, Patel MR, Tanguay JF, Ricco JB, Debus ES, Mazzolai L, Bauersachs R, Verhamme P, Bosch J, Nikol S, Nehler M, Aboyans V, Violi F.

Thromb Haemost. 2019 Apr;119(4):576-585. doi: 10.1055/s-0039-1678527. Epub 2019 Jan 31. Review.

PMID:
30703812
35.

ABC (Atrial fibrillation Better Care) Pathway and Healthcare Costs in Atrial Fibrillation: The ATHERO-AF Study.

Pastori D, Farcomeni A, Pignatelli P, Violi F, Lip GY.

Am J Med. 2019 Jul;132(7):856-861. doi: 10.1016/j.amjmed.2019.01.003. Epub 2019 Jan 16.

PMID:
30659810
36.

Atrial fibrillation and human immunodeficiency virus type-1 infection: a systematic review. Implications for anticoagulant and antiarrhythmic therapy.

Pastori D, Mezzaroma I, Pignatelli P, Violi F, Lip GYH.

Br J Clin Pharmacol. 2019 Mar;85(3):508-515. doi: 10.1111/bcp.13837. Epub 2019 Jan 11.

37.

Digoxin and Platelet Activation in Patients With Atrial Fibrillation: In Vivo and In Vitro Study.

Pastori D, Carnevale R, Nocella C, Bartimoccia S, Novo M, Cammisotto V, Piconese S, Santulli M, Vasaturo F, Violi F, Pignatelli P; Atherosclerosis in Atrial Fibrillation (ATHERO‐AF) Study Group.

J Am Heart Assoc. 2018 Nov 20;7(22):e009509. doi: 10.1161/JAHA.118.009509.

38.

Integrated Care Management of Patients With Atrial Fibrillation and Risk of Cardiovascular Events: The ABC (Atrial fibrillation Better Care) Pathway in the ATHERO-AF Study Cohort.

Pastori D, Pignatelli P, Menichelli D, Violi F, Lip GYH.

Mayo Clin Proc. 2019 Jul;94(7):1261-1267. doi: 10.1016/j.mayocp.2018.10.022. Epub 2018 Dec 11.

PMID:
30551910
39.

Remnant Lipoprotein Cholesterol and Cardiovascular and Cerebrovascular Events in Patients with Non-Alcoholic Fatty Liver Disease.

Pastori D, Baratta F, Novo M, Cocomello N, Violi F, Angelico F, Del Ben M.

J Clin Med. 2018 Oct 23;7(11). pii: E378. doi: 10.3390/jcm7110378.

40.

Blood Hormones and Venous Thromboembolic Events: Lack of Association or Lack of Standardization?

Pastori D, Violi F.

Thromb Haemost. 2018 Nov;118(11):1847-1849. doi: 10.1055/s-0038-1675176. Epub 2018 Oct 12.

PMID:
30312977
41.

A Simple Clinical Risk Score (C2HEST) for Predicting Incident Atrial Fibrillation in Asian Subjects: Derivation in 471,446 Chinese Subjects, With Internal Validation and External Application in 451,199 Korean Subjects.

Li YG, Pastori D, Farcomeni A, Yang PS, Jang E, Joung B, Wang YT, Guo YT, Lip GYH.

Chest. 2019 Mar;155(3):510-518. doi: 10.1016/j.chest.2018.09.011. Epub 2018 Oct 4.

42.

Anticoagulant therapy in patients with liver cirrhosis and portal vein thrombosis: insights for the clinician.

Basili S, Pastori D, Raparelli V, Violi F.

Therap Adv Gastroenterol. 2018 Sep 6;11:1756284818793561. doi: 10.1177/1756284818793561. eCollection 2018. Review.

43.

Correction to: Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study.

Raparelli V, Pastori D, Pignataro SF, Vestri AR, Pignatelli P, Cangemi R, Proietti M, Davì G, Hiatt WR, Lip GYH, Corazza GR, Perticone F, Violi F, Basili S; ARAPACIS Study Collaborators.

Intern Emerg Med. 2018 Dec;13(8):1349. doi: 10.1007/s11739-018-1922-y.

PMID:
30076553
44.

Antioxidant activity from extra virgin olive oil via inhibition of hydrogen peroxide-mediated NADPH-oxidase 2 activation.

Carnevale R, Nocella C, Cammisotto V, Bartimoccia S, Monticolo R, D'Amico A, Stefanini L, Pagano F, Pastori D, Cangemi R, Violi F.

Nutrition. 2018 Nov;55-56:36-40. doi: 10.1016/j.nut.2018.03.045. Epub 2018 Mar 29.

PMID:
29960154
45.

Left atrial thrombus resolution in non-valvular atrial fibrillation or flutter: biomarker substudy results from a prospective study with rivaroxaban (X-TRA).

Miyazawa K, Pastori D, Hammerstingl C, Cappato R, Meng IL, Kramer F, Cohen A, Schulz A, Eickels MV, Lip GYH, Marin F.

Ann Med. 2018 Sep;50(6):511-518. doi: 10.1080/07853890.2018.1495337.

PMID:
29956554
46.

Time to therapeutic range (TtTR), anticoagulation control, and cardiovascular events in vitamin K antagonists-naive patients with atrial fibrillation.

Pastori D, Pignatelli P, Cribari F, Carnevale R, Saliola M, Violi F, Lip GY.

Am Heart J. 2018 Jun;200:32-36. doi: 10.1016/j.ahj.2018.03.004. Epub 2018 Mar 10.

PMID:
29898846
47.

Rivaroxaban for stroke prevention in people with atrial fibrillation and diabetes mellitus.

Li YG, Pastori D, Lip GYH.

Diabet Med. 2018 Aug;35(8):1134-1135. doi: 10.1111/dme.13685. Epub 2018 Jul 4. No abstract available.

PMID:
29790596
48.

Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants.

Pastori D, Lip GYH, Farcomeni A, Del Sole F, Sciacqua A, Perticone F, Marcucci R, Grifoni E, Pignatelli P, Violi F; ATHERO-AF study group.

Int J Cardiol. 2018 Aug 1;264:58-63. doi: 10.1016/j.ijcard.2018.01.097.

PMID:
29776574
49.

Gut-derived lipopolysaccharides increase post-prandial oxidative stress via Nox2 activation in patients with impaired fasting glucose tolerance: effect of extra-virgin olive oil.

Carnevale R, Pastori D, Nocella C, Cammisotto V, Bartimoccia S, Novo M, Del Ben M, Farcomeni A, Angelico F, Violi F.

Eur J Nutr. 2019 Mar;58(2):843-851. doi: 10.1007/s00394-018-1718-x. Epub 2018 May 16.

PMID:
29766292
50.

Blood hydrogen peroxide break-down activity in healthy subjects and in patients at risk of cardiovascular events.

Carnevale R, Nocella C, Pignatelli P, Bartimoccia S, Stefanini L, Basili S, Novo M, D'Amico A, Cammisotto V, Pastori D, Violi F.

Atherosclerosis. 2018 Jul;274:29-34. doi: 10.1016/j.atherosclerosis.2018.04.025. Epub 2018 Apr 25.

PMID:
29747088

Supplemental Content

Loading ...
Support Center